Equities research analysts predict that Amarin Co. plc (NASDAQ:AMRN) will post ($0.08) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Amarin’s earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.07). Amarin posted earnings per share of ($0.05) in the same quarter last year, which would suggest a negative year-over-year growth rate of 60%. The company is expected to report its next earnings report on Wednesday, August 1st.
According to Zacks, analysts expect that Amarin will report full year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.42) to ($0.31). For the next financial year, analysts forecast that the business will report earnings of $0.08 per share, with EPS estimates ranging from ($0.16) to $0.27. Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for Amarin.
Amarin (NASDAQ:AMRN) last issued its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). The firm had revenue of $43.80 million during the quarter, compared to analyst estimates of $43.75 million. The business’s revenue for the quarter was up 26.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.08) earnings per share.
NASDAQ:AMRN traded down $0.01 during trading hours on Friday, reaching $3.26. The company had a trading volume of 48,384 shares, compared to its average volume of 2,106,325. Amarin has a one year low of $2.66 and a one year high of $4.60. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -13.16 and a beta of 0.81. The company has a debt-to-equity ratio of -2.30, a current ratio of 1.74 and a quick ratio of 1.45.
In other Amarin news, General Counsel Joseph T. Kennedy sold 26,942 shares of the company’s stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $2.90, for a total value of $78,131.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 4.08% of the company’s stock.
Large investors have recently made changes to their positions in the business. Paloma Partners Management Co bought a new stake in shares of Amarin during the fourth quarter worth $141,000. Hoylecohen LLC bought a new stake in shares of Amarin during the fourth quarter worth $142,000. Private Advisor Group LLC grew its holdings in shares of Amarin by 81.8% during the first quarter. Private Advisor Group LLC now owns 64,293 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 28,929 shares during the last quarter. DRW Securities LLC grew its holdings in shares of Amarin by 45.1% during the first quarter. DRW Securities LLC now owns 80,400 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Claraphi Advisory Network LLC grew its holdings in shares of Amarin by 637.3% during the first quarter. Claraphi Advisory Network LLC now owns 85,309 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 73,738 shares during the last quarter. Hedge funds and other institutional investors own 42.51% of the company’s stock.
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.